Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
1
Interinstitutional Multidisciplinary Biobank, IRCCS San Raffaele Pisana, 00166 Rome, Italy
2
Department of Systems Medicine, Medical Oncology, University of Rome Tor Vergata, 00133 Rome, Italy
3
Department of Human Sciences & Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy
4
Department of Enterprise Engineering, University of Rome “Tor Vergata”, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(1), 95; https://doi.org/10.3390/cancers11010095
Received: 14 November 2018
/
Revised: 7 December 2018
/
Accepted: 8 January 2019
/
Published: 15 January 2019
(This article belongs to the Special Issue The Role of Thrombosis and Haemostasis in Cancer)
Risk prediction of chemotherapy-associated venous thromboembolism (VTE) is a compelling challenge in contemporary oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Current guidelines do not recommend thromboprophylaxis for primary prevention, but assessment of the patient’s individual risk of VTE prior to chemotherapy is generally advocated. In recent years, efforts have been devoted to building accurate predictive tools for VTE risk assessment in cancer patients. This review focuses on candidate biomarkers and prediction models currently under investigation, considering their advantages and disadvantages, and discussing their diagnostic performance and potential pitfalls.
View Full-Text
Keywords:
venous thromboembolism; biomarkers; clinical decision systems; risk assessment models; machine learning
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Riondino, S.; Ferroni, P.; Zanzotto, F.M.; Roselli, M.; Guadagni, F. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers 2019, 11, 95. https://doi.org/10.3390/cancers11010095
AMA Style
Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers. 2019; 11(1):95. https://doi.org/10.3390/cancers11010095
Chicago/Turabian StyleRiondino, Silvia, Patrizia Ferroni, Fabio M. Zanzotto, Mario Roselli, and Fiorella Guadagni. 2019. "Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models" Cancers 11, no. 1: 95. https://doi.org/10.3390/cancers11010095
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
